GlassScriptPhysician profile
Aleda A Toma
NPI 1104870344
$4,848.50
in general payments reported to CMS, 2019-2025
46 companies · $896 in 2025
The $896 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $184 · 2021: $559 · 2022: $857 · 2023: $1,161 · 2024: $901 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.36 |
| Education | $678.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,325.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $372.96 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $295.26 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.74 | 2019-2024 | Opdivo, Eliquis |
| Array Biopharma INC | $213.80 | 2022-2025 | Mektovi, Braftovi, Lorbrena |
| Celgene Corporation | $191.69 | 2021-2024 | Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $156.42 | 2021-2025 | Ojjaara, Zejula, Jemperli |
| Genzyme Corporation | $146.91 | 2019-2022 | |
| Genentech USA, INC. | $141.19 | 2019-2025 | Lunsumio, Polivy, Columvi |
| Abbvie INC. | $133.21 | 2024-2025 | |
| Astellas Pharma US INC | $127.64 | 2019-2025 | Xtandi, Padcev |
| Eisai INC. | $106.90 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $105.30 | 2019-2023 | Imbruvica |
| Sumitomo Pharma America, INC. | $103.42 | 2023-2025 | Orgovyx |
| Daiichi Sankyo INC. | $99.95 | 2020-2025 | Enhertu |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleda Toma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.